Review on Herbal medicines of Alzheimer’s Disease

Sushmita V. Patil; Vaishnavi K. Patil; Paresh A. Patil

doi:10.5958/2231-5659.2020.00033.8

Asian Journal of Research in Pharmaceutical Sciences

ISSN

2231-5659 (Online)
2231-5640 (Print)

Submit Article

Review on Herbal medicines of Alzheimer’s Disease

Author(s): Sushmita V. Patil, Vaishnavi K. Patil, Paresh A. Patil

Email(s): rcp.pareshpatil@gmail.com

DOI: 10.5958/2231-5659.2020.00033.8

Address: Ms. Sushmita V. Patil, Ms. Vaishnavi K. Patil, Mr. Paresh A. Patil
Ahinsa Institute of Pharmacy, Dondaicha, Tal-Shindkheda, Dhule. (MS) 425408 India.
*Corresponding Author

Published In: Volume - 10, Issue - 3, Year - 2020

View HTML

View PDF

ABSTRACT:
Alzheimer s disease (AD) is characterized by an menacing loss of recollection, connected purposeful refuse, and behavioral disorder. Patients may liver for more than a decade after they are diagnosed with AD, making it the important cause of disability in the aged. The treatments of alternative in AD are cholinesterase inhibitors and NMDA-receptor Antagonists. As cholinergic purpose is requisite for short-term memory, the cholinergic shortage in AD was also supposed to be accountable for much of the short-term memory shortage. Herbal medicine products have been used in the handling of Behavioral and Psychological Symptoms of Dementia (BPSD) but with different responses. Although some Food and Drug Administration-approved drugs are accessible for the treatment of AD, the outcomes are often insufficient, and there is a place for herbal medicine. The prearranged assessment recognized two herbs and herbal formulations for the treatment of AD: Melissa officinalis, Salvia officinalis and Yi-Gan San and BDW (Ba Wei Di Huang Wan). Ginkgo biloba All five herbs are useful for cognitive injury of AD. These herbs and formulations have confirmed good therapeutic usefulness but these results need to be compare with those of conventional drugs.

Keywords:

Cite this article:
Sushmita V. Patil, Vaishnavi K. Patil, Paresh A. Patil. Review on Herbal medicines of Alzheimer’s Disease. Asian J. Res. Pharm. Sci. 2020; 10(3):171-177. doi: 10.5958/2231-5659.2020.00033.8

Cite(Electronic):
Sushmita V. Patil, Vaishnavi K. Patil, Paresh A. Patil. Review on Herbal medicines of Alzheimer’s Disease. Asian J. Res. Pharm. Sci. 2020; 10(3):171-177. doi: 10.5958/2231-5659.2020.00033.8 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2020-10-3-10

REFERENCES:

1. Shahin Akhondzadeh, Seyed Hesameddin Abbasi. Herbal medicine in the treatment of Alzheimer's disease, American Journal of Alzheimer's Disease and Other Dementias, Volume 21, Number 2, March/April 2006, Page 113 – 118.

2. Katzman R: The Prevalence and Malignancy of Alzheimer's disease. A Major Killer. Arch Neurol. 1976; 33: 217-218.

3. Evans DA, Funkenstein HH, Albert MS: Prevalence of Alzheimer's disease in a community population of older persons: Higher than previously reported. JAMA. 1989; 262: 2551-2556.

4. Geldmacher DS, Whitehouse PJ: Differential diagnosis of Alzheimer's disease. Neurology. 1997; 48(Suppl 6): S2-S9. 4. World Health Organization: The ICD-JIO Classification ofMental and Behavioral Disorders. Geneva: World Health Organization, 1992.

5. Leopoldo Luiz dos Santos-Neto, Maria Alice de Vilhena Toledo, Patrı´cia Medeiros-Souza and Gustavo Almeida de Souza, “The Use of Herbal Medicine in Alzheimer’s Disease—A Systematic Review” Advance Access Publication 23 October 2006 eCAM 2006;3(4)441–445 doi:10.1093/ecam/nel071.

6. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice parameter: management of dementia (an evidence-based review). Neurology 2001;56: 1154–66.

7. Jones RW, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer’s disease. An analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging 2004; 21:607–20.

8. Fran¸cois C, Sintonen H, Sulkava R, Rive B. Cost effectiveness of Memantine in moderately severe Alzheimer’s’ Disease. A Markov model in Finland. Clin Drug Invest 2004; 24:373–84.

9. Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, et al. Economic evaluation of donezepil in moderate to severe Alzheimer disease. Neurology 2004;63: 644–50.

10. Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, et al. Efficacy of donepezil in mild cognitive impairment. A randomized placebo-controlled trial. Neurology 2004; 63:651–7.

11. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomized double-blind trial. Lancet 2004; 363:2105–15.

12. Mantle D, Pickering AT, Perry E. Medical Plant extracts for treatment of dementia. A review of their pharmacology, efficacy and tolerability. CNS Drugs 2000;13: 201–13.

13. World Health Organization: The ICD-JIO Classification ofMentaland Behavioral Disorders. Geneva: World Health Organization,1992.

14. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994.

15. McKhann G. Drachman D, Folstein M, et al.: Clinical diagnosis of AD: Report ofNINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on AD. Neuiology. 1984; 34: 939-944.2

16. Schneiders LS: An overview of rating scales used in dementia. Alzheimer Insights. 1996; 2: 1-7.

17. Selkoe DJ: Amyloid beta-protein and genetics of Alzheimer's disease. JBiol Chem. 1996; 27: 18295-18298.

18. Lue LF, Kuo YM, Roher AE: Soluble amyloid beta peptide concentration as a predictor of synaptic changes in Alzheimer's disease. AmJ Pathol. 1999; 155: 853-862.

19. Francis PT, Palmer AM, Snape M, et al.: The cholinergic, Veurozsurg Psj'chiatrjl 1999; 54: 137-147.

20. Wright CI, Geula C, Mesulam MM: Neurological cholinesterase in the normal brain and in Alzheimer's disease: Relation to plaques, tangles, and patterns of selective vulnerability. Ann Neurol. 1993; 34: 3 73-384.

21. Davies P, Maloney AJ: Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976; 2: 1457-1459.

22. Livingston G. Katona C: How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis. Int J Geriatric Psychiatry 2000; 15: 203-207.

23. Giacobini E: Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer's disease. Alzheimer Dis Assoc Disord. 2000; 14: S3-S I 1.

24. Nordberg A, Svensson AL: Cholinesterase inhibitors in the treatment of Alzheimer's disease: A comparison of tolerability and pharmacology. Drug Safey. 1998; 19: 465-480.

25. Weinstock M: Selectivity of cholinesterase inhibition: Clinical implication for the treatment of Alzheimer's Dise'ase. CNS Drugs. 1999; 12: 307-303.

26. Bullock R: Drug treatment in dementia. Curr Opin Psychiatry 2001; 14: 349-353.

27. Bullock R: New drugs for Alzheimer's disease and other dementias. Br JPsychiatry. 2002; 180: 135-139.

28. Keltner NL, Beth Williams SN: Memantine: A new approach to Alzheimer's disease. Perspect Psychiatric Care. 2004; 40: 123-124.

29. Akhondzadeh S, Noroozian M: Alzheimer's disease: Pathophysiology and pharmacotherapy. IDrugs. 2002; 4: 1167-1172.

30. Bullock R: New drugs for Alzheimer's disease and other dementias. Br JPsychiatry. 2002; 180: 135-139.

31. Shadlen MF, Larson EB: What's new in Alzheimer's disease treatment? Reasons for optimism about future pharmacologic options. Postgrad Med. 1999; 105: 109-118.

32. Mayeux R, Sano M: Treatment ofAlzheimer's disease. NEngl J Med. 1999; 34: 1670-1679.

33. Bush Al: Therapeutic targets in the biology ofAlzheimer's disease. Curr Opin Psychiatry. 2001; 14: 341-348.

34. Raskind MA, Peskind ER, Wessel T: Galantamine in AD: A six month randomized placebo-controlled trial with a six month extension. Neurology. 2000; 54: 2261-2268.

35. Kanowski S, Hoerr R: Proof of the efficacy of the Ginkgo biloba special extract egb76 1 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type of multi-infarct dementia. Phytomedicine. 1997; 4: 215-222.

36. Le Bars PL, Katz MM, Berman N, et al.: A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA. 1997; 278: 1327-1332.

37. De Feudis FV: Ginkgo biloba Extract EGb761. Pharmacological Activities and Clinical Applications. Paris: Elsevier, 1991.

38. Kleijnen J: Ginkgo biloba. Lancet 1992; 340: 1136-1139.

39. Wettstein A: Cholinesterase inhibitors and ginkgo extracts-are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration. Phytomedicine. 2000; 6: 393-40 1.

40. Dore S, Bastianetto S, Kar S, et al: Protective and rescuing abilities of IGF-I and some putative free radical scavengers against betaamyloid- inducing toxicity in neurons. Ann N YAcad Sci. 1999; 890: 356-364.

41. Kanowski S, Hoerr R: Ginkgo biloba extract EGb 761 in dementia: Intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry. 2003; 36: 297-303.

42. Schulz V: Ginkgo extract or cholinesterase inhibitors in patients with dementia: What clinical trials and guidelines fail to consider. Phytomedicine. 2003; 10(Suppl) 14: 74-79.

43. Kurz A, Van Baelen B: Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: A review based on meta-analyses by the Cochrane collaboration. Dementia Geriatr Cogn Disord. 2004; 18: 217-226.

44. Xu SS, Gao ZX, Weng Z: Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Zhongguo Yao Li XueBao. 1995; 16: 391-395.

45. Zhang RW, Tang XC, Han YY: Drug evaluation of huperzine A in the treatment of senile memory disorders [in Chinese; English abstract]. Zhongguo Yao LiXue Bao. 1991; 12: 250-252.

46. Zhang Z, Wang X, Chen Q: Clinical efficacy and safety of huperzine alpha in treatment of mild to moderate Alzheimer disease: A placebo-controlled, double-blind, randomized trial. Zhonghua Yi XueZaZhi. 2002; 82: 941-944.

47. Xu SS, Cai ZY, Qu ZW: Huperzine-A in capsules and tablets for treating patients with Alzheimer disease. Zhongguo Yao Li Xue Bao. 1999; 20: 486-490.

48. Szatmari SZ, Whitehouse PJ: Vinpocetine for cognitive impairment and dementia; Cochrane Database Syst Rev. 2003; CD003 119.

49. Hindmarch I, Fuchs HH, Erzigkeit H: Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol. 1991; 6: 31-43.

50. Balestreri R, Fontana L, Astengo F: A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. JAm Geriatr Soc. 1987; 35: 425 -430.

51. Fenzl E, Apecechea M, Schaltenbrand R: Efficacy and tolerance of vinpocetine administered intravenously, in addition of standard therapy, to patients suffering from an apoplectic insult. In Krieglstein J (ed): Pharmacology of Cerebral Ischemia. Proceedings of the International Symposium on Pharmacology of Cerebral Ischemia. New York: Elsevier Science Publishers; 1986: 430-434.

52. Manconi E, Binaghi F, Pitzus F: A double-blind clinical trial of vinpocetine in the treatment of cerebral insufficiency of vascular and degenerative origin. Curr Ther Res Clin Exp. 1986; 30: 702-709.

53. Peruzza M, DeJacobis M: A double-blind placebo controlled evaluation of the efficacy and safety of vinpocetine in the treatment of patients with chronic vascular or degenerative senile cerebral dysfunction. Adv Ther. 1986; 3: 201-209.

54. Blaha L, Erzigkeit H, Adamczyk A: Clinical evidence of the effectiveness of vinpocetine in the treatment of organic psychosyndrome. Hum Psychopharmacol. 1989; 4: 103-1 1 1.

55. Perry EK, Pikering AT, Wang WW, et al.: Medicinal plants and Alzheimer's disease: Integrating ethnobotanical and contemporary scientific evidence. JAltern Complement Med 1998; 4: 419-428.

56. Perry EK, Pikering AT, Wang WW, et al.: Medicinal plants and Alzheimer's disease: From etnobotany to phytotherapy. J Pharm Pharmacol. 1999; 51: 527-534.

57. Kennedy DO, ScholeyAB, Tildesley NTJ, et al.: Modulation ofmood and cognitive performance following acute administration of Melissa officinalis lemon balm. Pharmacol Biochem Behav. 2002; 72: 953-964.

58. Akhondzadeh S, Noroozian M, Mohammadi M, et al.: Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: A double blind, randomised, placebo controlled trial. JNeurol Neurosurg Psychiatry. 2003; 74: 863-866.

59. Akhondzadeh S, Noroozian M, Mohammadi M, et al.: Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: A double blind, randomized and placebo-controlled trial. J Clin Pharm Ther 2003; 28: 53-59.

60. Wake G, Court J, Pikering A, et al.: CNS acetylcholine receptor activity in European medicinal plants traditionally used to improve failing memory. JEthnopharmacol. 2000; 69: 105-114.

61. Schulz V, Hansel R, Tyler VE: Rational Phytotherapy. A Physicians 'Guide to Herbal Medicine, 3rd ed. Berlin: Springer- Verlag, 1998.

62. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12.

63. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–44.

64. Khan KS, Daya S, Jadad AR. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med 1996;156: 661–6.

65. Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomized and placebo-controlled trial. J Clin Pharm Ther 2003;28:53–9.

66. Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomized and placebocontrolled trial. J Neurol Neurosurg Psychiatr 2003;74:863–6.

67. Iwasaki K, Satoh-Nakagawa T, Maruyama M, Monma Y, Nemoto M, Tomita N e cols. A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatr 2005;66:248–52.

68. Iwasaki K, Kobayashi S, Chimura Y, Taguchi M, Inoue K, Cho S e cols. A randomized, double-blind, placebo-controlled clinical trial of the Chinese herbal medicine ‘Ba Wei Huang Wan’ in the treatment of dementia. J Am Geriatr Soc 1994;52:1518–21.

69. Birks J, Grimley EJ. Ginkgo biloba for cognitive impairment and dementia. The Cochrane Library, Issue 2, 2004. Oxford: Update Software.

70. http://clinicaltrials.gov/ct/how/NCT00083590?order¼9.

Asian Journal of Research in Pharmaceutical Sciences (AJPSci) is an international, peer-reviewed journal, devoted to pharmaceutical sciences....... Read more >>>

RNI: Not Available
DOI: 10.52711/2231-5659